Given the MMR gene-specific (MLH1, PMS2, MSH2, MSH6) differences regarding the age of cancer occurrence [3], it is essential to determine optimal screening protocols separately for each MMR protein abnormality detected by immunohistochemistry. The gene discussed is MSH6; the disease is cancer.